IL146311A0 - Carboxylic acid derivatives that inhibit the binding of integrins to their receptors - Google Patents

Carboxylic acid derivatives that inhibit the binding of integrins to their receptors

Info

Publication number
IL146311A0
IL146311A0 IL14631100A IL14631100A IL146311A0 IL 146311 A0 IL146311 A0 IL 146311A0 IL 14631100 A IL14631100 A IL 14631100A IL 14631100 A IL14631100 A IL 14631100A IL 146311 A0 IL146311 A0 IL 146311A0
Authority
IL
Israel
Prior art keywords
binding
receptors
inhibit
integrins
carboxylic acid
Prior art date
Application number
IL14631100A
Other languages
English (en)
Original Assignee
Texas Biotechnology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas Biotechnology Corp filed Critical Texas Biotechnology Corp
Publication of IL146311A0 publication Critical patent/IL146311A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL14631100A 1999-05-07 2000-05-05 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors IL146311A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13297199P 1999-05-07 1999-05-07
PCT/US2000/012303 WO2000067746A1 (en) 1999-05-07 2000-05-05 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors

Publications (1)

Publication Number Publication Date
IL146311A0 true IL146311A0 (en) 2002-07-25

Family

ID=22456441

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14631100A IL146311A0 (en) 1999-05-07 2000-05-05 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
IL146311A IL146311A (en) 1999-05-07 2001-11-01 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL146311A IL146311A (en) 1999-05-07 2001-11-01 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors

Country Status (23)

Country Link
EP (1) EP1176956B1 (de)
JP (1) JP5132855B2 (de)
AT (1) ATE383153T1 (de)
AU (1) AU5267900A (de)
CA (1) CA2373360C (de)
CY (1) CY1107438T1 (de)
CZ (1) CZ303312B6 (de)
DE (1) DE60037726T2 (de)
DK (1) DK1176956T3 (de)
ES (1) ES2296625T3 (de)
IL (2) IL146311A0 (de)
IN (1) IN2001KN01110A (de)
MX (1) MXPA01011340A (de)
NO (1) NO324421B1 (de)
NZ (1) NZ515248A (de)
PL (1) PL205322B1 (de)
RO (1) RO122246B1 (de)
RU (1) RU2263109C2 (de)
SI (1) SI20744B (de)
SK (1) SK286696B6 (de)
TR (2) TR200201920T2 (de)
WO (1) WO2000067746A1 (de)
ZA (1) ZA200108774B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972296B2 (en) * 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
US6723711B2 (en) * 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
AR026748A1 (es) 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
ES2200617B1 (es) 2001-01-19 2005-05-01 Almirall Prodesfarma, S.A. Derivados de urea como antagonistas de integrinas alfa 4.
SI21096B (sl) * 2001-10-09 2012-05-31 Encysive Pharmaceuticals Inc Derivati karboksilne kisline ki inhibirajo vezavo integrinov na njihove receptorje
ATE448784T1 (de) * 2002-02-14 2009-12-15 Pharmacia Corp Substituierte pyridinone als modulatoren für p38 map kinase
PL374598A1 (en) 2002-06-28 2005-10-31 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
AU2003265398A1 (en) 2002-08-09 2004-02-25 Transtech Pharma, Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
CA2513493A1 (en) * 2002-11-08 2004-05-27 Schering Corporation Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds
US7612091B2 (en) 2002-12-20 2009-11-03 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
PE20050159A1 (es) 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
US7544699B2 (en) 2003-08-08 2009-06-09 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
US7501538B2 (en) 2003-08-08 2009-03-10 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
EP1917244A2 (de) 2005-08-24 2008-05-07 Abbott GmbH & Co. KG Hetaryl substituierte guanidinverbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
WO2008109991A1 (en) * 2007-03-09 2008-09-18 University Health Network Inhibitors of carnitine palmitoyltransferase and treating cancer
CA2694724C (en) 2007-08-01 2017-09-12 University Health Network Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer
WO2010126914A1 (en) * 2009-04-27 2010-11-04 Elan Pharmaceuticals, Inc. Pyridinone antagonists of alpha-4 integrins
WO2012033548A2 (en) * 2010-09-07 2012-03-15 E. I. Du Pont De Nemours And Company Herbicidal bis-nitrogen-containing oxo and sulfono heterocycles
KR101828094B1 (ko) 2009-09-09 2018-03-22 이 아이 듀폰 디 네모아 앤드 캄파니 제초제 피리미돈 유도체
DK2810937T3 (en) * 2012-01-31 2017-03-13 Daiichi Sankyo Co Ltd PYRIDONE DERIVATIVES
JP6537500B2 (ja) 2013-09-20 2019-07-03 ビオマリン プハルマセウトイカル インコーポレイテッド 疾患治療用のグルコシルセラミドシンターゼ阻害剤
KR20170052526A (ko) 2014-03-13 2017-05-12 프로테나 바이오사이언시즈 리미티드 다발성 경화증에 대한 병용 치료
MX382781B (es) * 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
US10246451B2 (en) * 2017-04-26 2019-04-02 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
US10875875B2 (en) * 2017-04-26 2020-12-29 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
EP3615087B1 (de) 2017-04-28 2023-09-06 Texas Children's Hospital Zielgerichtete nanopartikel
CN112105616B (zh) * 2018-02-02 2023-09-01 基因技术公司 药学化合物、其盐类、其制剂和其制备和使用方法
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリンの阻害のための化合物
ES3013256T3 (en) 2018-10-30 2025-04-11 Gilead Sciences Inc Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
FI3873884T3 (fi) 2018-10-30 2025-02-24 Gilead Sciences Inc 3-(kinolin-8-yyli)-1,4-dihydropyrido[3,4-d]pyrimidiini-2,4-dionijohdannaisia alfa-4-beta-7-integriinin estäjinä tulehdussairauksien hoidossa
EP3873605B1 (de) 2018-10-30 2024-10-23 Gilead Sciences, Inc. Verbindungen zur inhibierung von alpha4-beta7-integrin
WO2021030438A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2614189A1 (de) * 1976-04-02 1977-10-20 Hoechst Ag Therapeutisch wirksame ureido- und semicarbazido-derivate des tiazols und verfahren zu ihrer herstellung
US5220017A (en) * 1991-04-10 1993-06-15 Merck & Co., Inc. Cholecystokinin antagonists
AU681396B2 (en) * 1993-03-31 1997-08-28 G.D. Searle & Co. 1-amidinophenyl-pyrrolidones piperidinones azetinones as platelet aggregation inhibitors
US5534529A (en) * 1993-06-30 1996-07-09 Sankyo Company, Limited Substituted aromatic amides and ureas derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
JPH07304755A (ja) * 1994-05-12 1995-11-21 Yamanouchi Pharmaceut Co Ltd 縮合ジアゼピン誘導体
US5610296A (en) * 1994-12-05 1997-03-11 G. D. Searle & Co. Process for the preparation of amidino phenyl pyrrolidine beta-alanine urea analogs
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
PT912901E (pt) * 1996-05-15 2002-04-29 Searle & Co Metedo e reagentes para monitorizacao dos niveis sanguineos de compostos antiagregantes plaquetares
WO1998011896A1 (en) * 1996-09-18 1998-03-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US6025358A (en) * 1998-06-11 2000-02-15 G. D. Searle & Co. Double prodrugs of potent GP IIb/IIIa antagonists
AU5991699A (en) * 1998-09-21 2000-04-10 Biochem Pharma Inc. Quinolizinones as integrin inhibitors

Also Published As

Publication number Publication date
CA2373360C (en) 2011-09-06
CZ20013963A3 (cs) 2002-04-17
DK1176956T3 (da) 2008-05-26
SI20744B (sl) 2009-08-31
SK286696B6 (sk) 2009-03-05
ZA200108774B (en) 2003-01-24
SI20744A (sl) 2002-06-30
WO2000067746A9 (en) 2002-08-29
ATE383153T1 (de) 2008-01-15
HK1045805A1 (en) 2002-12-13
EP1176956A4 (de) 2002-08-28
NO324421B1 (no) 2007-10-08
PL351396A1 (en) 2003-04-07
WO2000067746A1 (en) 2000-11-16
JP2002544161A (ja) 2002-12-24
CY1107438T1 (el) 2012-12-19
RU2263109C2 (ru) 2005-10-27
DE60037726D1 (de) 2008-02-21
JP5132855B2 (ja) 2013-01-30
TR200103178T2 (tr) 2002-05-21
NO20015418L (no) 2001-12-21
IL146311A (en) 2011-10-31
RO122246B1 (ro) 2009-03-30
DE60037726T2 (de) 2009-03-05
AU5267900A (en) 2000-11-21
ES2296625T3 (es) 2008-05-01
PL205322B1 (pl) 2010-04-30
CA2373360A1 (en) 2000-11-16
TR200201920T2 (tr) 2002-09-23
IN2001KN01110A (de) 2015-06-05
CZ303312B6 (cs) 2012-07-25
EP1176956A1 (de) 2002-02-06
NZ515248A (en) 2004-01-30
NO20015418D0 (no) 2001-11-06
EP1176956B1 (de) 2008-01-09
WO2000067746A8 (en) 2002-02-28
MXPA01011340A (es) 2003-08-01
SK16082001A3 (sk) 2002-04-04

Similar Documents

Publication Publication Date Title
IL146311A0 (en) Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
EP1203766B8 (de) Carbonsäurederivate, die die Bindung von Integrinen an ihre Rezeptoren hemmen
IL138973A0 (en) Compounds that inhibit the binding of integrins to their receptors
IL146312A0 (en) Propanoic acid derivatives that inhibit the binding of integrins to their receptors
CA2361285A1 (en) Propanoic acid derivatives that inhibit the binding of integrins to their receptors

Legal Events

Date Code Title Description
FF Patent granted